Spots Global Cancer Trial Database for nerlynx
Every month we try and update this database with for nerlynx cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer | NCT00300781 | Breast Neoplasm... Neoplasms | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer | NCT01827267 | HER2-mutant Non... | neratinib temsirolimus | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer | NCT00300781 | Breast Neoplasm... Neoplasms | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating HKI-272 in Tumors | NCT00146172 | Breast Neoplasm... | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | NCT00445458 | Advanced Breast... Advanced Malign... Breast Neoplasm... | HKI-272 Paclitaxel | 18 Years - | Puma Biotechnology, Inc. | |
| Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | NCT01111825 | Breast Cancer | Temsirolimus Neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | NCT00777101 | Advanced Breast... Breast Cancer | Neratinib Lapatinib Capecitabine | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating HKI-272 in Tumors | NCT00146172 | Breast Neoplasm... | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting | NCT01808573 | HER2+ Metastati... | neratinib capecitabine lapatinib | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | NCT00777101 | Advanced Breast... Breast Cancer | Neratinib Lapatinib Capecitabine | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating HKI-272 in Tumors | NCT00146172 | Breast Neoplasm... | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer | NCT00398567 | Advanced Breast... | HKI-272 trastuzumab | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | NCT00777101 | Advanced Breast... Breast Cancer | Neratinib Lapatinib Capecitabine | 18 Years - | Puma Biotechnology, Inc. | |
| A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors | NCT00397046 | Tumors | neratinib | 20 Years - | Puma Biotechnology, Inc. | |
| A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors | NCT00397046 | Tumors | neratinib | 20 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | NCT00706030 | Breast Cancer Advanced Malign... | neratinib vinorelbine | 18 Years - | Puma Biotechnology, Inc. | |
| Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer | NCT01111825 | Breast Cancer | Temsirolimus Neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | NCT00777101 | Advanced Breast... Breast Cancer | Neratinib Lapatinib Capecitabine | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating HKI-272 in Tumors | NCT00146172 | Breast Neoplasm... | neratinib | 18 Years - | Puma Biotechnology, Inc. | |
| Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations | NCT01953926 | Solid Tumors Ha... | Neratinib Fulvestrant Trastuzumab Paclitaxel | 18 Years - | Puma Biotechnology, Inc. | |
| Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer | NCT00266877 | Carcinoma, Non-... Lung Neoplasms | HKI-272 | 18 Years - | Puma Biotechnology, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
